ArticleMaterials today. Bio2025
A ROS-responsive nanocarrier co-delivering cerium nanozymes and thalidomide for synergistic ulcerative colitis therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic and recurrent inflammatory disorder of the gastrointestinal tract, posing major clinical challenges due to its increasing incidence and complex pathogenesis involving immune dysregulation and oxidative stress. Current therapies are often limited by poor efficacy and severe side effects, leaving an urgent need for improved treatments. Here, we present a novel ROS-responsive nanocarrier (TPN) for the synergistic therapy of colitis via ROS scavenging and immune modulation. TPN were fabricated by encapsulating cerium oxide nanozymes (Ceria NPs) and thalidomide (Tha) within a specially designed amphiphilic ROS-responsive polymer (PP). TPN exhibited strong ROS-scavenging activity and ROS-triggered Tha release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.